Deadline Note

Proposals may be submitted from September 1, 2009 to October 1, 2009 and January 15, 2010 to February 15, 2010.

Synopsis

The NBM program supports fundamental research in biomechanics and nanomechanics.

Deadline Note

Optional letters of intent are due on February 15, 2010. Full applications are due on April 27, 2010.

Synopsis

The purpose of this project is to support state, major urban, and tribal public health agencies, national organizations and state coalitions to improve maternal, infant, child, and reproductive health through the application of evidence-based approaches. Additionally, as one of the goals of the Division of Reproductive Health is to promote partnerships at the local, state, tribal, and national levels, this project highlights the importance of engaging partners in the applied sciences process including analysis of relevant data, interpretation of results, and translation of findings to public health practice.

Deadline Note

The deadline for receipt of optional letters of intent is February 15, 2010. The deadline for receipt of full applications is March 15, 2010.

Synopsis

The sponsor invites applications for the competing continuation of the Pediatric Acute Liver Failure Study Group. This FOA will utilize the NIH Cooperative Agreement (U01) grant mechanism.

Deadline Note

The deadline for receipt of optional letters of intent is February 15, 2010. The deadline for receipt of full applications is March 15, 2010.

Synopsis

The sponsor invites applications for the competing continuation of the Adult Acute Liver Failure Study Group. This FOA will utilize the NIH Cooperative Agreement (U01) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after February 16, 2010. The deadline for receipt of optional letters of intent is February 16, 2010. The deadline for receipt of full applications is March 15, 2010.

Synopsis

The sponsor invites projects that address research endeavors in specific areas that will benefit from significant three-year funds without the expectation of continued NIH funding beyond this period. The research supported by the program should have high short-term impact, and a high likelihood of enabling growth and investment in biomedical research and development, public health, and health care delivery. Applicants may propose to address either a specific disease- or technology-related research question relevant to the mission of one or more participating Institutes and Centers, or propose the creation of a unique infrastructure/resource designed to accelerate scientific progress in the future. All NIH Institutes and Centers with funding authority will participate with the NIH Office of the Director in this initiative. This FOA will be administered by the Office of the Director of the NIH (http://www.nih.gov). Awards will be administered by the participating Institutes and Centers. This FOA will utilize the NIH RC4 award mechanism.

Deadline Note

This program will expire on May 8, 2010.

Synopsis

The sponsor offers support for Small Research Grant (R03) applications. The R03 grant mechanism supports different types of health services research projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and, development of new research technology.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2009. This program will expire on November 17, 2011.

Synopsis

The sponsor provides support for a wide variety of research designs in order to improve the quality, safety, effectiveness, and efficiency of health care through the implementation and use of health IT. These designs include: small pilot and feasibility or self-contained health IT research projects; secondary data analysis of health IT research; and economic (prospective or retrospective) analyses of health IT implementation and use. Through economic analyses estimates of health IT implementation and use costs and benefits will be generated. This program will use the NIH Small Research Grant (R03) award mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2009. This program will expire on November 17, 2011.

Synopsis

The sponsor provides support for short-term preparatory, pilot or feasibility studies that will inform larger scale real world health IT implementation and use or the conduct of more comprehensive health IT implementation research. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Synopsis

The purpose of the Advanced Education Nursing (AEN) Program is to provide funding for projects to prepare advanced education nurses through the enhancement of advanced nursing education and practice.

Synopsis

The Bureau of Reclamation (Reclamation) manages 348 reservoirs in the 17 Western States. Reclamation also manages,(with partners), 289 recreation sites that have over 90 million visits annually. As required under Executive Order 12962 “Recreational Fisheries,” dated June 7, 1995, Reclamation is responsible for increasing public awareness of recreational opportunities at these reservoirs. Since 1992, Reclamation has provided support for fishing events that benefit disabled and disadvantaged children at its reservoirs. The previous contractors/recipients were organized to join professional sport fishing volunteers with disabled and disadvantaged children for a day of outdoor recreational fishing. These fishing events are designed to create an environment in which both children and volunteers will benefit by each one bringing to the event their own experiences and lessons to share. Because the scope of these proposed events will involve not just government entities but also volunteers from local communities, the recipient will need to seek other volunteer assistance to fulfill this purpose. This will also increase awareness of disabled and disadvantaged children in local communities.

Deadline Note

The due date for Step 1 proposals is February 16, 2010. The sponsor will invite successful applicants from the Step 1 process to submit a Step 2 proposal, which will be due on April 20, 2010.

Synopsis

The sponsor solicits ground-based proposals for the Space Radiation Program Element (SRPE) components of the Human Research Program (HRP). Proposals are solicited by the SRPE in the area of Space Radiation Biology utilizing beams of high energy heavy ions simulating space radiation at the NASA Space Radiation Laboratory (NSRL), at Brookhaven National Laboratory (BNL) in Upton, New York.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 16, 2009. The deadlines for receipt of standard R01 applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2012.

Synopsis

The sponsor invites grant applications for studies that focus on research to define factors affecting energy balance and to define mechanisms influencing cancer risk, prognosis, and quality of life. These studies may range from new analyses of existing datasets to additional collection of data and biological specimens in ongoing investigations. It is anticipated that the knowledge gained will provide additional information to better understand the relationships among energy balance, cancer risk, and prognosis. This FOA will use the NIH Research Project (R01) award mechanism.

Deadline Note

The deadlines for receipt of standard R01 applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on January 8, 2012.

Synopsis

The sponsor invites applications for research projects that investigate the effects of Erythropoietin (EPO) on tumor cell growth. EPO has been widely used to relieve the anemia associated with renal failure. In addition, EPO and other erythropoiesis stimulating agents (ESAs) have recently been used to treat the anemia associated with cancer chemotherapy. However, several clinical trials involving administration of ESAs, have suggested that ESAs may accelerate tumor progression and increase mortality in cancer patients. It is therefore important to understand the biology of ESAs on tumor cell growth and apoptosis. The purpose of this FOA is to stimulate high quality research on the effects of ESAs on tumor cell biology and tumor progression. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 18, 2009. The deadlines for receipt of standard R21 applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2012.

Synopsis

The sponsors invite applications for basic, pre-clinical, and clinical complementary cancer research. The research should relate to the areas of prevention, diagnosis, and treatment of cancer as well as management of cancer symptoms and side effects due to conventional cancer treatment. In addition, this FOA encourages the development and application of emerging and innovative technologies, including identification of novel therapeutics in the pharmacopoeia of Traditional Medical Systems (as defined by the World Health Organization), use of complementary approaches to improve the therapeutic ratio of standard and investigational anti-cancer therapies, and research on lifestyle modifications (e.g. diet, exercise, mind-body approaches) for their impact on cancer outcomes (e.g., response to conventional cancer therapy, survival). The overarching goals of this FOA is to encourage investigators to submit high quality, preliminary research of humans that will advance the science of Complementary and Alternative Medicine (CAM) and provide a solid foundation and justification for future research project (R01) grant applications to definitively determine the efficacy of CAM approaches. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 18, 2009. The deadlines for receipt of standard R03 applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2012.

Synopsis

The sponsor invites applications for basic, pre-clinical, and clinical complementary cancer research. The research should relate to the areas of prevention, diagnosis, and treatment of cancer as well as management of cancer symptoms and side effects due to conventional cancer treatment. In addition, this FOA encourages the development and application of emerging and innovative technologies, including identification of novel therapeutics in the pharmacopoeia of Traditional Medical Systems (as defined by the World Health Organization), use of complementary approaches to improve the therapeutic ratio of standard and investigational anti-cancer therapies, and research on lifestyle modifications (e.g. diet, exercise, mind-body approaches) for their impact on cancer outcomes (e.g., response to conventional cancer therapy, survival). The overarching goals of this FOA is to encourage investigators to submit high quality, preliminary research of humans that will advance the science of Complementary and Alternative Medicine (CAM) and provide a solid foundation and justification for future research project (R01) grant applications to definitively determine the efficacy of CAM approaches. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources. This program will use the NIH Small Research Grant (R03) award mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after September 16, 2009. The deadlines for receipt of standard R01 applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on September 8, 2012.

Synopsis

The sponsor invites research grant applications from institutions/organizations for the development and validation of biomarkers for: a) early detection, prediction of progression, and recurrence of hematopoietic malignancies, especially in high-risk individuals; and, b) for risk assessment of primary and secondary hematopoietic malignancies. This FOA is also encourages the development and improvement of specific technologies and methods for quantitative detection of novel biomarkers associated with hematopoietic malignancies. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after September 16, 2009. The deadlines for receipt of standard R01 applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on September 8, 2012.

Synopsis

The sponsor invites applications from institutions/organizations on the discovery and characterization of non-coding (nc) RNAs in preneoplasias and early stage cancers to: 1) improve early cancer detection, intervention, and prevention; 2) predict risk of progression from preneoplasia to cancer, and 3) distinguish benign lesions from precancerous lesions. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 16, 2009. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2012.

Synopsis

The sponsors invite the submission of applications in developmental and formative behavioral research in cancer prevention and control. This FOA will support innovative pilot projects or feasibility studies, which will facilitate the growth of research science in the cancer control continuum from a behavioral perspective. This FOA includes and incorporates the research interests of the Behavioral Research program, the Office of Cancer Survivorship, and the Community Oncology and Prevention Trials Research Group. This FOA is appropriate for testing timely interventions in pilot studies for feasibility or using rigorous qualitative research methods to assess the potential efficacy of an intervention. It is also appropriate for the psychometric evaluation of new measures or culturally appropriate ones to be adapted for use in populations where measures have not yet been developed or validated. This FOA encourages applications that include small cross-disciplinary teams of investigators who bring perspectives from the behavioral and social sciences, as well as other fields of public health. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 16, 2009. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2012.

Synopsis

The sponsor invites grant applications for research entailing the use of health claims data for cancer surveillance. Cancer surveillance may include assessment of patterns of care, quality, and outcomes of care, and health disparities across the continuum of treatment. The objective of this FOA is to encourage R03 grant applications from individuals who are interested in carrying out small research projects that are designed to expand our understanding of the validity of and methods needed to use claims data for cancer surveillance. Responses to this FOA may also include pilot analyses needed to provide preliminary data for larger grant proposals. This program will use the NIH Small Research Grant (R03) award mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 16, 2009. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2012.

Synopsis

The sponsor invites grant applications for research entailing the use of health claims data for cancer surveillance. Cancer surveillance may include assessment of patterns of care, quality, and outcomes of care, and health disparities across the continuum of treatment. The objective of this Funding Opportunity Announcement (FOA) is to encourage R21 grant applications from individuals who are interested in carrying out exploratory/ developmental research projects that are designed to expand our understanding of the validity of and methods needed to use claims data for cancer surveillance. Responses to this FOA may also include pilot analyses needed to provide preliminary data for larger grant proposals. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after September 16, 2009. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on September 8, 2012.

Synopsis

The sponsors invite applications for clinical and preclinical research to determine how diet and dietary factors, including dietary supplements, impact DNA methylation, histone posttranslational modification, noncoding RNA, and other epigenetic processes involved in cancer prevention and development. Another important aim of this FOA is to encourage collaborations between nutrition and epigenetic experts to study bioactive food components with cancer-preventative properties and to examine key epigenetic events in cancer processes (e.g., carcinogen metabolism, cell division, differentiation, and apoptosis) in order to begin to establish linkages between epigenetics, methylation patterns, and tumor incidences/behaviors. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2010. The deadlines for receipt of standard R01 applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on January 8, 2013.

Synopsis

The sponsors invite applications that propose to: (1) conduct evaluation research on obesity-related “natural experiments” (defined here as community and other population-level public policy interventions that may affect diet and physical activity behavior), and/or (2) develop and/or validate relevant community-level measures (instruments and methodologies to assess the food and physical activity environments at the community level). The overarching goal of this FOA is to inform public policy and research relevant to (1) diet and physical activity behavior, and (2) weight and health outcomes of Americans. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2010. The deadlines for receipt of standard R01 applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on January 8, 2013.

Synopsis

The sponsors invite applications that propose to: (1) conduct evaluation research on obesity-related “natural experiments” (defined here as community and other population-level public policy interventions that may affect diet and physical activity behavior), and/or (2) develop and/or validate relevant community-level measures (instruments and methodologies to assess the food and physical activity environments at the community level). The overarching goal of this FOA is to inform public policy and research relevant to (1) diet and physical activity behavior, and (2) weight and health outcomes of Americans. This program will use the NIH Small Research Grant (R03) award mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2010. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on January 8, 2013.

Synopsis

The sponsor invites research applications that propose to evaluate profiles of methylation, histone modifications and micro RNA (miRNA) and their association with risk of developing cancer in different populations. The overarching goal of this FOA is to provide support for population based studies to define the role of epigenetic markers (methylation, histone and micro RNA profiles) changes to understand cancer etiology. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2010. The deadlines for receipt of standard R01 applications under this announcement are: February 16, June 16 and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on January 8, 2013.

Synopsis

The sponsors invite applications that propose to: (1) foster multidisciplinary research that will evaluate how policies (federal, state and school district levels) can influence school physical activity and nutrition environments, youths’ obesogenic behaviors (e.g., nutrition and physical activity behaviors), and weight outcomes; (2) understand how schools are implementing these policies and examine multi-level influences on adoption and implementation at various levels (e.g., federal, state, school district, and school); and (3) understand the synergistic or counteractive effect of school nutrition and physical activity polices on the home and community environment and body weight. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2010. The deadlines for receipt of standard R01 applications under this announcement are: February 16, June 16 and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on January 8, 2013.

Synopsis

The sponsors invite applications that propose to: (1) foster multidisciplinary research that will evaluate how policies (federal, state and school district levels) can influence school physical activity and nutrition environments, youths’ obesogenic behaviors (e.g., nutrition and physical activity behaviors), and weight outcomes; (2) understand how schools are implementing these policies and examine multi-level influences on adoption and implementation at various levels (e.g., federal, state, school district, and school); and (3) understand the synergistic or counteractive effect of school nutrition and physical activity polices on the home and community environment and body weight. This program will use the NIH Small Research Grant (R03) award mechanism.

Deadline Note

This program will expire on September 8, 2012.

Synopsis

The sponsor provides support for the development of novel technologies for capturing, enriching, and preserving exfoliated abnormal cells from body fluids or effusions as well as methods for concentrating the tumor-derived sub-cellular material for use in biomarker studies. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 16, 2009. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2012.

Synopsis

The sponsor invites research applications from institutions and organizations to evaluate the utility and pilot the application of new strategies for determining prognosis or predicting response to therapy for cancer. The purpose of this FOA is to develop newly discovered biomarkers from initial correlative observations into assays or test systems suitable for use in clinical trials or other types of confirmatory clinical research studies. This program will provide tools whose purpose is to improve clinical decision-making in the care of cancer patients. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2011.

Synopsis

The sponsor offers support for research to: improve the measurement of racial /ethnic discrimination in health care delivery systems through improved instrumentation, data collection and statistical/analytical techniques; enhance understanding of the influence of racial/ethnic discrimination in health care delivery and its association with disparities in disease incidence, treatment and outcomes among disadvantaged racial/ethnic minority groups; and reduce the prevalence of racial/ethnic health disparities through the development of interventions to reduce the influence of racial/ethnic discrimination on health care delivery systems in the United States. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

This program will expire on September 8, 2011.

Synopsis

The sponsors offer support for individual-investigators or small groups to collaborate with the NIH Roadmap for Medical Research National Centers for Biomedical Computing (NCBCs). The intention of the collaborating projects is to engage researchers across the nation in building an excellent biomedical computing environment, using the computational tools and biological and behavioral application drivers of the funded NCBCs as foundation stones. This FOA is intended to support exploratory biomedical informatics and computational biology research—applications should be innovative, with high risk/high impact in new areas that are lacking preliminary data or development. This program will use the NIH Exploratory/Developmental (R21) grant mechanism. This PAR is developed as a Roadmap affiliated initiative.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 16, 2008. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2011.

Synopsis

The sponsor offers support for research that will enhance the understanding of the relationship between exposures to bioactive food components and/or environmental chemicals in utero , hormonal and growth factor response, gene expression or epigenetic changes and subsequent mammary cancer risk in preclinical models. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2009. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on January 8, 2012. Electronic application submission is required for this FOA. The new Adobe versions of the application forms are not yet available. Please check back in December to download the application package.

Synopsis

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 16, 2008. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2011.

Synopsis

The sponsor offers support the research on all aspects of stem cell biology, including research into the molecular and biochemical regulation of embryonic and adult stem cell behavior, with the goal of ultimately improving the specificity and long-term effectiveness of cancer therapy, through the targeting of those cells most responsible for disease progression and metastasis. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on November 6, 2011.

Synopsis

The sponsor offers support for projects that enhance the state-of-the-science on the causes of obesity and to inform Federal decision making on effective public health interventions for reducing the rate of obesity in the United States. This FOA is also intended to promote collaborative activities between researchers trained in economics and researchers specializing in public health, cancer, cardiovascular diseases, and other chronic diseases so that the desired goals can be more efficiently, quickly, and successfully attained. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2011.

Synopsis

The sponsor provides support for translational correlative studies that utilize annotated tumor and/or other biospecimens collected during large-scale multi-institutional clinical and/or prevention trials, respectively, with a goal to facilitate predictions of responses to current interventions, and inspire future development of improved therapeutic and preventive strategies. Projects proposed in response to this FOA should address the correlations between intervention outcomes and cancer patients’ disease characteristics determined at various cellular/molecular levels. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 16, 2008. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2011.

Synopsis

The sponsor offers support for research proposals focused on identifying protein biomarkers for cancers where etiology of the disease is attributed to infectious agents. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

This program will expire on January 8, 2011.

Synopsis

The sponsor offers support for research projects that will enhance understanding of human decision-making processes so that individuals can make more informed and satisfying choices regarding their health. The NCI encourages collaborations between basic judgment and decision-making researchers, and applied cancer control researchers that will elucidate single-event decision-making processes at the level of the individual patient or health care provider that are pertinent to cancer prevention, detection, treatment, survivorship, or end-of-life care. For the purpose of this initiative, a single-event decision is defined as a discrete decision made at a specific point in time. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after February 5, 2008. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2011.

Synopsis

The sponsor offers support for research to: improve the measurement of racial /ethnic discrimination in health care delivery systems through improved instrumentation, data collection and statistical/analytical techniques; enhance understanding of the influence of racial/ethnic discrimination in health care delivery and its association with disparities in disease incidence, treatment and outcomes among disadvantaged racial/ethnic minority groups; and reduce the prevalence of racial/ethnic health disparities through the development of interventions to reduce the influence of racial/ethnic discrimination on health care delivery systems in the United States. This program will use the NIH Small Research Grant (R03) award mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on January 8, 2011.

Synopsis

The sponsors offer support for research to critically evaluate the use of exfoliated cells to monitor the physiological effects of dietary bioactive food components thought to be involved with cancer prevention. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 16, 2009. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on March 6, 2009.

Synopsis

The sponsors applications that propose multidisciplinary research on potential reduced-exposure tobacco products, both smoked and smokeless. The multidisciplinary studies can span basic, biological, behavioral, surveillance, and epidemiology research. The tobacco industry is currently promoting several new products with claims that they: a) are less either harmful or less addictive; and b) purportedly deliver lower amounts of toxic, carcinogenic, and/or addictive agents to the user compared with conventional products. However, to date, the scientific evidence is insufficient to evaluate whether these new products actually reduce the users’ exposure or risk for tobacco-related diseases. The overarching goal of this FOA is to determine whether potential reduced-exposure tobacco products provide a truly, less-harmful alternative to conventional tobacco products, both at the individual and population level. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2009.

Synopsis

The sponsors offers support for Exploratory/Developmental Research Grant applications (R21) to investigate ethical issues in human subjects research. The purpose of this funding opportunity announcement is to solicit research addressing the ethical challenges of human subjects research in order to optimize the protection of human subjects and enhance the ethical conduct of human subjects research.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 2, May 1, and September 1 annually. This program will expire on September 8, 2010.

Synopsis

The sponsors offers support for research grant applications to investigate ethical issues in human subjects research. The purpose of this funding opportunity announcement is to solicit research addressing the ethical challenges of human subjects research in order to optimize the protection of human subjects and enhance the ethical conduct of human subjects research. This program will use the NIH Small Research Grant (R03) award mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 16, 2009. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2012.

Synopsis

The sponsor invites research applications from institutions and organizations to evaluate the utility and pilot the application of new strategies for determining prognosis or predicting response to therapy for cancer. The purpose of this FOA is to develop biomarkers from initial correlative observations into assays or test systems suitable for use in clinical trials or other types of confirmatory clinical research studies. This program will provide tools whose purpose is to improve clinical decision-making in the care of cancer patients. This FOA will use the NIH Exploratory/Developmental Phase II Research Grant (R33) mechanism.

Deadline Note

This program will expire on January 8, 2011.

Synopsis

The sponsors offers support aimed at enhancing nanoscience and nanotechnology research focused on problems in biology and medicine. Nanoscience and nanotechnology refer to research and development on the understanding and control of matter at a length scale of approximately 1 - 100 nanometers, where novel properties and functions occur because of the size. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2010. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on January 8, 2013.

Synopsis

The sponsor invites research applications from clinicians, epidemiologists, geneticists, statisticians, and translational researchers working in the field of cancer control and prevention to improve existing models for cancer risk and prognosis by developing innovative research projects that use existing data; develop new models for cancer risk and prognosis; and validate new models and evaluate their utility in research and clinic settings. To explore this opportunity, the NCI Division of Cancer Control and Population Sciences (DCCPS) and the Division of Cancer Treatment and Diagnosis (DCTD) encourage applications for research projects to develop, apply, and evaluate new and existing cancer risk and prognostic prediction models for use by researchers, clinicians, and the general public. This FOA is designed to provide a mechanism of support for investigators to address two major challenges in model development, which are: integrating diverse types of data (e.g., clinical, demographic, pathologic, environmental, epidemiologic, outcomes, and genetic data from varied data marts or warehouses); and ensuring adequate validation (i.e., using multiple separate populations to define sensitivity, specificity, and positive and negative predictive values). This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

This program will expire on March 17, 2010.

Synopsis

The sponsors provide support for exploratory/developmental nutrition and cancer prevention research. Specifically, this initiative seeks to promote cancer prevention research to identify and characterize molecular targets for bioactive food components. A bioactive food component is defined as a dietary constituent that has a health benefit by altering one or more cellular processes when provided in quantities over and beyond that needed for basic nutrition. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2011.

Synopsis

The sponsor provides support for research efforts aimed at establishing the physiological significance of dietary components in modulating the tumoricidal cell activity of natural killer (NK) cells for cancer prevention. The focus of research projects proposed in response to this FOA should be on defining the minimum quantity and duration of exposure to specific dietary components to modulate tumoricidal cell activity of NK cells for cancer prevention and the underlying mechanism(s) accounting for this response. Proposed projects must include animal and/or human investigations to be considered responsive to this announcement. Highly purified populations of immune cells, specific tumor cells such as RMA-S that lack class I MHC expression, target cell-free system, or single-cell assays may be used to define the molecular basis for the diet-induced changes in tumoricidal activity. However, the in vitro studies are only to be used to support in vivo studies and should not constitute the primary focus of the application. Molecular targets for food components may be examined at the sites of the tumoricidal cell receptors and cancer cell specific ligands, the output of tumoricidal cytokines (e.g., IFN-g), and the release of lytic granules such as a granulysin, perforin, and serine proteases (granzymes). This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

The deadlines for receipt of standard R21 applications under this announcement are: June 16, October 16, and February 16 annually. The deadlines for AIDS and AIDS-related applications are: May 7, September 7, and January 7 annually. This program will expire on May 8, 2011.

Synopsis

The purpose of the sponsor's program is to stimulate the development and validation of novel mitochondrial (mt) DNA biomarkers for early detection, diagnosis, prognosis, and risk assessment of cancer. This FOA will stimulate research on mutations in mtDNA for identification of additional indicators of tumor development and progression, including mitochondrial somatic mutations and mitochondrial haplogroups. This program will use the NIH Research Project (R21) award mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on September 8, 2011.

Synopsis

The sponsors provide support for hypothesis-driven projects exploring associations between the built environment, other contextual features of where people of all ages live and work and health behaviors related to energy balance. These projects should use population level data from health surveys and other large health studies. It is expected that the proposed projects will be designed to add/include contextual variables at diverse levels of geographic aggregation to such studies on behaviors that affect individual energy balance and thereby health. Subsequent analyses should be aimed at understanding the relative importance of the contextual variables (including home, work, school, and/or other environments) as determinants of energy balance-related health behaviors. Grant applications will be expected to use population level data from diverse sources for: 1) generation and addition of new geographic information system (GIS) data layers for analysis of contextual variables such as measures of the built and natural environments, to existing studies; 2) analyses of existing confidential geographic-based data either on site, at survey data centers, or other protected sites; and/or 3) merging multiple health-related data resources to allow new analyses of associations between contextual variables and energy balance-related health behaviors. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on September 8, 2011.

Synopsis

The sponsor provides support for innovative research across multiple disciplines for a better understanding of the biology, etiology, detection, prevention, and treatment of pancreatic cancer. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on September 8, 2011.

Synopsis

The sponsor provides support for innovative research across multiple disciplines for a better understanding of the biology, etiology, detection, prevention, and treatment of pancreatic cancer. This program will use the NIH Small Research Grant (R03) award mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on September 8, 2011.

Synopsis

The sponsor provides support for research projects focused on the identification and characterization of diet-induced changes in inflammation linked to colon cancer risks. This FOA is designed to stimulate research efforts that will lead to the identification and characterization of: diet-induced changes in anti- and pro-inflammatory mediators that modulate colon cancer risk; b) genetic polymorphisms that modify the responses to specific bioactive food components with regard to colon cancer inhibition; and c) the physiological effectiveness of dietary components in terms of concentration, activity, duration of exposure, degrees of stability, chemical forms, and receptor-binding affinity in inflammatory colonocytes. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after September 16, 2008. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on September 16, 2011.

Synopsis

The sponsors provide support for research projects focused on the development and implementation of effective communication strategies related to diet and health. Specifically, this FOA is designed to promote interdisciplinary research, conducted at multiple levels (e.g., individual, community/environment, and policy) and across diverse populations, to evaluate effective communication approaches for changing dietary behaviors. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after September 16, 2008. The deadlines for receipt of standard R01 applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on September 8, 2011.

Synopsis

The sponsors provide support for grant applications that: (a) address the etiology and etiologic mechanisms of hepatocellular carcinoma (HCC); (b) propose development of animal models for HCC; (c) propose novel approaches to prevent HCC malignancy; (d) propose therapeutic or diagnostic tools for reliable prognostic indicators for HCC; and/or (e) develop therapeutic approaches to minimize morbidity and mortality associated with HCC in humans. The primary focus of the proposed project must be on the basic biology, prevention, and/or treatment of liver cancer. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2009. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on September 8, 2012.

Synopsis

The sponsor provides support for applications from institutions and organizations that are interested in developing and testing innovative methods in cancer detection, diagnosis, and prognosis. The NCI is especially interested in research studies that focus on the development and testing of improved methods for detecting specific characteristics of cancer, which can be subsequently used for the clinical management of cancer patients or individuals who are at risk for (developing) cancer. It is important that research studies focus on the search for molecular and cellular differences between tumors, pre-malignant, or normal tissues. The studies should determine the clinical translational significance of these differences by correlation with clinical parameters, in order to answer clinical problems related to detection, diagnosis, treatment, and prognosis. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2010.

Synopsis

The sponsor solicits applications from organizations proposing to develop, characterize or improve animal models for human disease or to improve diagnosis and control diseases of laboratory animals that may interfere with research. Models to be considered must be applicable to the research interests of two or more categorical NIH Institutes/Centers. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2010. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on January 8, 2013.

Synopsis

The sponsor invites applications for large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study’s rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a well-documented Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. The Clinical Study Planning Grant is designed to facilitate activities central to the refinement of a study’s protocol and procedures and the development of a detailed MOP. The NEI Clinical Study Planning Grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures and/or assess recruitment potential. The Clinical Study Planning Grant is applicable to both epidemiologic and clinical trial research studies. This FOA will utilize the Clinical Study Planning Grant Program for Clinical Trials (R34) mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after September 16, 2009. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on September 8, 2012.

Synopsis

The sponsor invites applications from institutions/organizations that propose to conduct secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects, wherein numerous data collection activities are required to meet each project’s specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project’s originally intended purpose. Data are not limited to that collected under NEI support but these data are of highest programmatic interest. The R21 may be used to develop new statistical methodologies or to test hypotheses using existing data. Applicants should consider the relevance of their proposed analyses to NEI programs and priorities as described in the “National Plan for Eye and Vision Research” available at http://www.nei.nih.gov. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2012.

Synopsis

The sponsors invites applications under the NIH Clinical Trial Planning Grant Program, the purpose of which is to provide support for the development of a Phase III clinical trial. This includes the establishment of the research team, the development of tools for data management and oversight of the research, the definition of recruitment strategies, and the finalization of the protocol and other essential elements of the study included in a manual of operations/procedures. The Clinical Trial Planning Grant is not designed for the collection of preliminary data or the conduct of pilot studies to support the rationale for a clinical trial. This FOA will utilize the Clinical Trial Planning Grant (R34) mechanism.

Synopsis

A -- RECIPIENT EPIDEMIOLOGY AND DONOR EVALUATION STUDY-III (REDS-III) – INTERNATIONAL SITES SOL NHLBI-HB-11-04 POC Tara Knox, Phone: 301-402-0834, Alison M Stang, Phone: 301-435-0359 WEB: FBO.gov Permalink https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-HB-11-04/listing.html E-MAIL: knoxt@nhlbi.nih.gov, stanga@nhlbi.nih.gov knoxt@nhlbi.nih.gov, stanga@nhlbi.nih.gov NAICS: 541712 The National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Department of Health and Human Services (HHS) anticipates that Request for Proposals (RFP) No. NHLBI-HB-11-04 will be available on or about October 30, 2009.The solicitation will be for the International Sites for the program entitled ‘Recipient Epidemiology and Donor Evaluation Study-III (REDS-III).' It is anticipated that up to four awards will be made under full and open competition to U.S. blood centers collaborating with foreign blood centers/blood banks in lowor middle income countries where HIV/AIDS is prevalent in January 2011 for a period of seven years. The goal of this highly structured, multicenter, donor-recipient epidemiology, laboratory, and clinical outcomes program is to advance public health by conducting critical research to improve transfusion practices and the safety and adequacy of the blood supply in the U.S. and in countries affectedby the AIDS epidemic. NHLBI plans to support one data coordinating center (DCC), one central laboratory, up to 4 domestic hubs, and up to 4 international collaborative programs involving U.S. investigators and investigators at international blood centers. This notice addresses the international hubs only. The REDS-IIIprogram will target the following blood banking and transfusion medicine areas:1) Donor targeted strategies; 2) blood banking; 3) transfusion practices in adult patients; and 4) education and training. The REDS-III International program shall include epidemiologic and survey research as well as laboratory investigations. Clinical trials in potential recipients of blood products are NOT within the purview of the REDS-III program. A comprehensive longitudinal donation and donor database from each foreign collection site containing information on all donations collected during the period of the contract shall also be established to enable study investigators to address important blood safety issues. The researchportfolios of the REDS-III Domestic and International programs will be fashioned in response to contemporary scientific questions that need to be addressed to advance blood transfusion safety in the U.S. and in countries where REDS-III international blood centers are located. The major objectives of the research in the REDS-III International program are: 1) assess and monitor the prevalence and incidence of HIV-1, HIV-2 and other existing as well as newly discovered infectious agents that pose a threat to blood safety; 2) assess risks of transfusion-transmitted infections; 3) assess the impact of existing and new blood donor screening methodologies on blood safety and availability; 4) evaluate characteristics and behaviors of blood donors including risk factors for acquiring HIV and otherblood-borne agents; and 5) evaluate the donation process for ways to improve the safety and adequacy of the blood supply. Some studies may also address transfusion recipient safety concerns such as evaluating non-infectious transfusion risks (e.g., alloimmunization) and ways to reduce their occurrence. The domestic hubs and the international programs will be supported by a DCC responsible for overall coordination, communications, data management, and analytical/statistical support. The domestic hubs and the international programs will also be supported by a central laboratory which will be responsible for the necessary infectious disease, molecular, genetic, immunological, hematological and other testing conducted in the U.S., and for serving as the REDS-III biospecimen repository. The infrastructure of the REDS-III international component shall consist of U.S. bloodcenters which have ongoing collaborative research arrangements with blood centers in low or middle income countries impacted by the HIV/AIDS epidemic. The blood centers participating in each international program must collect a total of atleast 250,000 blood donations annually from at least three collaborating foreign collection sites. The foreign collection sites should be geographically dispersed and, whenever possible, be representative of the varying prevalence of HIV in the region(s)/country of interest. Each foreign blood collection site must collect a minimum of 25,000 donations annually. The infrastructure shall include a centralized data collection center (CCC) responsible for compiling donor/donation data and protocol specific data from participating blood centers within each country before being submitted to the REDS-III DCC. The offeror must meet the following three (3) mandatory qualification criteria at the time of receipt of proposal to be considered any further for award: 1.The offeror shall be a U.S. bloodcenter, blood bank, or academic institution (henceforth referred to as a U.S. blood center) with an established collaborative program with a foreign blood center or blood bank in a low or middle income country where HIV/AIDS is prevalent. 2.The offeror shall provide evidence of scientific collaborations with proposed foreign site investigator(s) that could include participating in research project(s) in the foreign country, publications, and/or conducting training programs in the foreign country. 3.To ensure the statistical relevance of the resulting data, the offeror shall provide evidence (e.g., official institutional letter certifying the information) that the proposed foreign blood collection sites locatedin a low or middle income country collect a total of at least 250,000 blood donations per year from at least three collaborating foreign collection sites within the same country, and that each of the sites collects a minimum of 25,000 annual blood donation. Each U.S. Blood Center will perform the following program requirements: 1) Manage the REDS-III international sites scope of work and study protocols and ensure transmission of complete and accurate scientific data from the foreign blood collection sites (subcontracts) to the REDS-III DCC, in accordance with procedures set forth in the protocols and Manuals of Procedures; 2) Manage through foreign subcontracts the collection of a minimum of 250,000 blood donations annually from at least three collaborating and geographically dispersed foreign collection sites located in a low or middle income country affected by the AIDS epidemic. Each foreign blood collection site must collect a minimum of 25,000 donations annually; 3) Propose epidemiologic, survey, and/or laboratory studies that will advance blood transfusion safety in the country of interest; 4) U.S. blood center Principal Investigator shall serve as a member of the REDS-III Oversight Committee; 5) U.S. blood center and foreign investigators shall serve as members of the REDS-III country-specific International Steering Committee; 6)U.S. blood center and foreign collection sites shall participate in, coordinate, and successfully conduct the REDS-III research protocols that have been approved by the REDS-III country-specific International Steering Committee; 7) Overseethe establishment and the management of a Centralized Data Collection Center (CCC); 8) Translate all materials to appropriate languages or dialects, or to English, as appropriate; 9) Oversee the collection, processing, testing, and storageof biospecimens by the foreign blood collection sites as required by study protocols; 10) In collaboration with the REDS-III central laboratory and the DCC, the U.S. blood center shall oversee the shipment of specific biospecimens of research interest to the U.S. for laboratory testing which for technical or financialreasons is better accomplished at the central laboratory (or at another US testing facility subcontracted by the central laboratory); 11) Administer approved surveys and ensure that the foreign blood collection sites incorporate study protocols into blood center operations, contact participants, distribute questionnaires, collect and process data, address donor inquiries, and provide data to the CCC; 12) Participate in all committee and subcommittee meetings, conference calls, and organizational training sessions of which the international site Investigators and staff are members; and 13) obtain all necessary governmental, administrative, and regulatory approvals to ensure participation in and successful completion of all studies included in the REDS-III country-specific research portfolio. This announcement is not a request for proposals (RFP). Although up to four awards are anticipated, the Government is not committed to award a contract pursuant to this announcement. The RFP will be available on the FedBizOpps web page at www.fedbizopps.gov. Prospective offerors are responsible for downloading the RFP and all attachments. It is also the offerors' responsibility to monitor the FedBizOpps web page for the release of any amendments to the RFP. The RFP will contain all the information and details to allow potential offerors to prepare andsubmit a contract proposal. This acquisition has been designated as a full and open competition under the North American Industry Classification System (NAICS)code 541712. Subcontracting opportunities are anticipated during the course of this contract award. All responsible sources may submit a proposal, which shall be considered by the NHLBI. CITE: https://www.fbo.gov/?s=opportunity&mode=form&id=3839506b2fe3d059595af41af2380453&tab=core&_cview=0 Posted 10/16/09 (W-SN01987155). (0289) (kww)

Synopsis

A -- RECIPIENT EPIDEMIOLOGY AND DONOR EVALUATION STUDY-III (REDS-III) – DOMESTIC SITES SOL NHLBI-HB-11-03 POC Tara Knox, Phone: 301-402-0834, Alliso M Stang, Phone: 301-435-0359 WEB: FBO.gov Permalink https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-HB-11-03/listing.html E-MAIL: knoxt@nhlbi.nih.gov, stanga@nhlbi.nih.gov knoxt@nhlbi.nih.gov, stanga@nhlbi.nih.gov NAICS: 541712 The National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Department of Health and Human Services (HHS) anticipates that Request for Proposals (RFP) No. NHLBI-HB-11-03 will be available on or about October 30, 2009. The solicitation will be for the Domestic Hubs for the program entitled ‘Recipient Epidemiology and Donor Evaluation Study-III (REDS-III).' It is anticipated that up to four awards will be made under full and open competition to domestic sites in January 2011 for a period of seven years. The goal of this highly structured, multicenter, donor-recipient epidemiology, laboratory, and clinical outcomes program is to advance public health by conducting critical research to improve transfusion practices and the safety and adequacy of the blood supply in the U.S. and in countries affected by the AIDS epidemic. NHLBI plans to support one data coordinating center (DCC), one central laboratory, up to four domestic hubs, and up to four international collaborative programs involving U.S. investigators and investigators at international blood centers. This notice addresses the domestic hubs only. The REDS-III program will target the following blood banking and transfusion medicine areas: 1) Donor targeted strategies; 2) blood banking; 3) transfusion practices in adult patients; and 4) education and training. The program will include survey, epidemiological and laboratory investigations. Clinical trials in potential recipients of blood products are NOT within the purview of the REDS-III program. The research portfolios of the REDS-III Domestic and International programs will be fashioned in response to contemporary scientific questions that need to be addressed to advance blood transfusion safety in the U.S. and in countries where REDS-III international blood centers are located. It isexpected that about one third of the studies conducted in the REDS-III Domesticprogram will address donor and/or donation safety and availability issues, and other blood banking questions; the remaining two thirds of the investigations will address adult transfusion recipient safety concerns. Comprehensive databases including information on donors and their donations/components, and on adult patients considered for, or receiving a transfusion will enable study investigatorswith the necessary scientific and analytical expertise to address in a timely fashion important scientific issues in blood banking and transfusion medicine. The domestic hubs and the international programs will be supported by a DCC responsible for overall coordination, communications, data management, and analytical/statistical support. The domestic hubs and the international programs will also be supported by a central laboratory which will be responsible for the necessaryinfectious disease, molecular, genetic, immunological, hematological and other testing conducted in the U.S., and for serving as the REDS-III biospecimen repository. The domestic component of the REDS-III program shall be structured to include geographically dispersed hubs with each hub consisting of a blood center and one or more transfusion services which support a mixed hospital base of tertiary care and community hospitals. This type of structure shall ensure access to demographically diverse adult patient populations, and access to services that perform most of the blood transfusions. The studies to be conducted in the REDS-III hospitals shall focus on adult patients. Hence, studies of pediatric in-hospital patient populations shall not be part of the REDS-III Domestic program. The offeror must meet the following two (2) mandatory qualification criteria at the time of receipt of proposal to be considered any further for award: 1) The offeror shall structure a hub consisting of a blood center and one or more transfusionservices which support a mixed hospital base of tertiary care and community hospitals. The hub shall be led by a Principal Investigator and Co-Principal Investigator. The Principal Investigator must work either at one of the hospital transfusion services or at the blood center. If based at a transfusion service, the Co-Principal Investigator must work at the blood center. Conversely, if the Principal Investigator is based at the blood center, the Co-Principal Investigator must be based at a transfusion service. Each hub shall be required to include a mix of tertiary (at least one) and community (at least one) hospitals to ensure access to diverse adult patient populations and representation of all required services. Each hub is required to have access to, and the demonstrated ability to interact successfully with, the following five hospital services: intensive care unit(s), cardiac surgery, orthopedic surgery, oncology/cancer center, and traumaservices. 2)To ensure the statistical relevance of the resulting data, the offeror shall provide evidence and supporting documentation for the last two years that at least 75,000 allogeneic donations per year were collected by the hub's blood center. Each domestic hub will perform the following program requirements: 1) Propose epidemiologic, survey, and/or laboratory studies that will advance blood transfusion safety in the U.S.; 2) Serve as a member of the REDS-III Oversight Committee; 3) Serve as a voting member of the REDS-III Domestic Steering Committee; 4) Develop and finalize REDS-III study protocols; 5) Ensure access to demographically diverse adult patient populations and services that perform most of the blood transfusions; 6) Include a blood center that collects a minimum of 75,000 allogeneic blood donations per year and serves as the major supplier of blood to the participating hospitals within the hub; 7) Participate in, coordinate, and successfully conduct the REDS-III research protocols that have been approvedby the REDS-III Domestic Steering Committee; 8) Serve as a Centralized Data Collection Center (CCC); 9) Collect, process, store, and ship biospecimens as required by study protocols; 10) Administer the REDS-III hub scope of work, includingstudy protocols, and transmit complete and accurate scientific data to the DataCoordinating Center, in accordance with procedures set forth in the protocols and Manuals of Operations, which shall be developed by the REDS-III investigatorsfor this program; 11) Participate in educational activities, such as the promotion of public and health care provider education by disseminating research results and/or conducting research methodology training; 12) Mentor a minimum of one junior investigator in the areas of blood banking and/or transfusion medicine starting in Year 2 of the program, and prepare the investigator to apply for NHBLIcareer development awards; 13) Participate in all committee and subcommittee meetings, conference calls, and other organizational training sessions of which the Principal Investigator, Co-Principal Investigator, Co-Investigators, Project Director, and hub center staff are members. It will be desirable that a total of at least 20,000 RBC transfusion exposures occur per year at the hub's participating hospitals/outpatient clinics. It would also be desirable, although not required, that the consortium of hospitals participating in the hub admitted the following minimum number of cross-matched adult patients each year at the following hospital services: 1) intensive care units, minimum of 1,000 cross-matched adultpatients per year; 2) cardiac surgery, minimum of 1,000 cross-matched adult patients per year; 3) orthopedic surgery, minimum of 500 cross-matched adult patients admitted per year; 4) oncology/cancer center, minimum of 1,000 cross-matched adult patients per year; and 5) trauma service, minimum of 1,000 cross-matched adult patients per year, or alternatively, participation in a level 1 trauma program. This announcement is not a request for proposals (RFP). Although up to fourawards are anticipated, the Government is not committed to award a contract pursuant to this announcement. The RFP will be available on the FedBizOpps web pageat www.fedbizopps.gov. Prospective offerors are responsible for downloading theRFP and all attachments. It is also the offerors' responsibility to monitor theFedBizOpps web page for the release of any amendments to the RFP. The RFP will contain all the information and details to allow potential offerors to prepare and submit a contract proposal. This acquisition has been designated as a full and open competition under the North American Industry Classification System (NAICS) code 541712. Subcontracting opportunities are anticipated during the course of this contract award. All responsible sources may submit a proposal, which shall be considered by the NHLBI. CITE: https://www.fbo.gov/?s=opportunity&mode=form&id=1a1835f11641fe883a039f3c9807dbe6&tab=core&_cview=0 Posted 10/16/09 (W-SN01987172). (0289) (kww)

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after September 5, 2009. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on September 8, 2012.

Synopsis

The sponsors invite applications that propose research on the roles of nutrition and physical activity in the development, prevention, and management of cardiovascular diseases (CVD) or pulmonary diseases. In particular, the FOA aims to (1) improve knowledge of the contribution of diet and physical activity to these conditions and how sleep influences these relationships, (2) increase the evidence base for refining public health recommendations and clinical guidelines regarding these lifestyle behaviors, and (3) develop and test strategies to improve the adoption of these recommendations. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2010. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. This program will expire on January 8, 2013.

Synopsis

The sponsor invites applications proposing pilot studies to obtain data that is critical for the design of robust clinical trials. This Funding Opportunity Announcement (FOA) should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial. Appropriate pilot studies might demonstrate feasibility of an intervention or an experimental design, estimate intervention parameters, or gather other data important for the design of a trial. Applications must demonstrate that the proposed pilot studies are both necessary and sufficient to permit the design of the clinical trial. During the evaluation of applications in response to this FOA, the review group will also consider the significance and potential public health impact of the full-scale clinical trial that would be proposed following the R34 award period. The NHLBI anticipates that the R34 award period will yield more competitive investigator-initiated clinical trial grant applications and more robust and successful clinical trials that evaluate interventions for the treatment or prevention of heart, lung, blood, or sleep disorders. This FOA will utilize the R34 grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2010. The deadlines for receipt of standard R21 applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on January 8, 2013.

Synopsis

The sponsor invites applications from investigators who propose to study topics that will determine blood banking and transfusion practice. The National Heart, Lung, and Blood Institute (NHLBI) is responsible for supporting research in blood banking and transfusion medicine. This research aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine is critical to public health since about five million patients receive blood transfusions every year in the U.S. Since blood transfusions pose infectious and non-infectious risks to recipients, it is important to understand the determinants of transfusion-associated adverse events and how best to minimize transfusion risks. It is also crucial to maintain an adequate blood supply by minimizing the risks associated with the donation process and developing enhanced recruitment and retention programs. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after September 16, 2009. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on September 8, 2012.

Synopsis

The sponsor invites applications that propose to define the factors and mechanisms controlling the differentiation of embryonic or adult stem or progenitor cells, either in vitro or in vivo. It is designed to stimulate new scientific advances in stem cell differentiation including technology research that may not be hypothesis driven. The long range goal of this program is the development of methods to direct the differentiation or development of stem cells along specific cell lineages to yield replacement cells for clinical use, whether the replacement cells are formed in vitro for delivery or formed in vivo in the tissue or organ environment. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2010. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on January 8, 2013.

Synopsis

The National Institutes of Health (NIH) Investigator-Initiated Small Grant (R03) funding opportunity supports small research projects that can be carried out in a short period of time with limited resources. Investigator-initiated research, also known as unsolicited research, is research funded as a result of an investigator submitting a research grant application to NIH in an investigator’s area of interest and competency. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This program will use the NIH Small Research Grant (R03) award mechanism.

Deadline Note

This program will expire on January 8, 2011.

Synopsis

The sponsors provide support for applications from institutions/organizations that propose to study the ethical, legal and social implications (ELSI) of human genome research. This announcement is specifically designed to: 1) encourage the development of small, focused research projects by legal, historical, ethics, humanities, social sciences and behavioral scholars; 2) support exploratory studies that may provide preliminary findings or pilot data for larger research proposals; 3) support the secondary analysis of existing data; 4) support the development of new methodologies; and 5) stimulate and facilitate the entry of promising new investigators into ELSI Research. This program will use the NIH Small Research Grant (R03) award mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16 and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on January 8, 2011.

Synopsis

The sponsors provide support for innovative high risk/high payoff research related to genomics, including analysis of genome structure and function, genetic variation, population genomics, and ELSI (ethical, legal, and social implications). NHGRI places a high priority on research projects that address technology and methods development in all relevant areas, new approaches to bioinformatics that facilitate data management and data dissemination, new computational biology approaches to data analysis, new strategies to apply genomics to clinical problems, new approaches that combine genomics and population studies, and studies of the ethical, legal and social implications of genomics research including the exploration of new policy approaches to address social issues raised by new capabilities in genomics. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

This program expires September 8, 2012

Synopsis

The sponsor provides support for research related to occupational safety and health. Eligible applicants are domestic and foreign for-profit or non-profit organizations, public or private institutions, such as universities, colleges, hospitals, and laboratories, units of state and local governments, eligible agencies of the federal government, faith-based or community based organizations, and Indian Tribes, Tribal Government, and/or Organizations. The R21 award mechanism will be used.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 5, 2009. This FOA will expire on September 8, 2012.

Synopsis

The sponsor provides support for projects designed to develop an understanding of the risks and conditions that are associated with occupational diseases and injuries, to explore methods for reducing risks and for preventing or minimizing exposure to hazardous conditions in the workplace, and to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources. This FOA will utilize the NIH Small Research Grant (R03) award mechanism,

Deadline Note

The deadline for receipt of optional letters of intent is one month prior to planned submission date. This program will expire on February 17, 2010.

Synopsis

The sponsors provide support for innovative exploratory/developmental investigations in primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for primary immunodeficiency diseases. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

The deadline for receipt of optional letters of intent is one month prior to planned submission date. This program will expire on February 17, 2010.

Synopsis

The sponsors provide support for innovative exploratory/developmental investigations in primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for primary immunodeficiency diseases. This program will use the NIH Small Research Grant (R03) award mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after September 5, 2008. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on September 8, 2011.

Synopsis

The sponsors provide support for research that will contribute to the overall understanding of vaccine safety. This research opportunity invites studies that address scientific areas potentially relevant to vaccine safety such as 1) physiological and immunological responses to vaccines and vaccine components, 2) how genetic variations affect immune/physiological responses that may impact vaccine safety, 3) identification of risk factors and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines, 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources such as passive reporting systems, or 5) the application of genomic/molecular technologies to improve knowledge of vaccine safety. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2010. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on January 8, 2013.

Synopsis

The sponsor provides support for Bioengineering Research Grants (BRGs) for basic and applied multi-disciplinary research that addresses important biological, bioengineering or medical research problems. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2009. The deadlines for receipt of standard R01 applications under this announcement are: February 5, June 5, and October 5 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. . Electronic application submission is required for this FOA. The new Adobe versions of the application forms are not yet available. Please check back in December to download the application package. This program will expire on January 8, 2012.

Synopsis

The sponsor invites R21 research grant applications that will inform interventions addressing the cultural and structural factors that produce high rates of unintended pregnancy across the reproductive age span, especially in low-income populations in the United States. These interventions can operate at a wide range of levels, from clinical interventions to interventions that influence cultural, economic, social, structural, and/or policy factors contributing to unintended pregnancy. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 18, 2009. The deadlines for receipt of standard R21 applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2012.

Synopsis

The sponsors invite investigator-initiated research grant applications from institutions/ organizations that propose to conduct behavioral and/or biomedical research aimed at better understanding the etiologies and precursors for, reducing risk for, and incidence of, teen dating violence (TDV). Research is also sought that examines the linkages and gaps among perceptions of appropriate responses to teen dating violence from service providers, the criminal justice system, teens themselves, victims, perpetrators and bystanders. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 16, 2009. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2012.

Synopsis

The sponsors provides support to enhance childhood obesity research by fostering the formation of local, state, or regional teams consisting of researchers, policymakers, and other relevant stakeholders (e.g., community representatives, public health practitioners or officials, educators) in order to identify research questions and hypotheses, design and implement the relevant research, and translate the research into evidence relevant to potential policy efforts in this area. This program will use the NIH Small Research Grant (R03) award mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on January 8, 2011.

Synopsis

The sponsors provide support for investigator-initiated research grant applications that seek to develop a comprehensive program of research focused on the mechanisms through which social, economic, cultural, and community-level factors, and their interactions, impact the early cognitive, neurobiological, socio-emotional, and physical development of children. This program will use the NIH Small Research Grant (R03) award mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 2, May 1, and September 1 annually. This program will expire on March 17, 2010.

Synopsis

The sponsor offers support for Small Research Grant (R03) applications from institutions/organizations that propose basic, clinical or translational research on the effects of the Fragile X pre-mutation on ovarian function, with a focus on premature ovarian failure or early menopause, in women and/or animal models. This program will use the NIH Small Research Grant (R03) award mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2008. This program will expire on January 8, 2011.

Synopsis

The sponsor provides support for applications from institutions/ organizations that propose to better understand the role of adipose tissue in the normal physiological regulation of reproduction, to discern its possible role in the etiology of diseases and disorders that impact human fertility, and to probe its potential importance in different racial/ethnic prevalence rates of certain reproductive disorders.This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on September 8, 2011.

Synopsis

The sponsors provide support for Research Project Small Grant applications from institutions/ organizations that propose to enhance our understanding of effective positive youth development programs and the mechanisms responsible for positive health and developmental outcomes. This will be accomplished through the development, implementation, and evaluation of new or improved positive youth development programs, the evaluation of existing “successful” programs, or the evaluation of effective, evidence-based, gender-inclusive programs that are adapted, translated, or disseminated for new populations of youth and adolescents. This program will use the NIH Small Research Grant (R03) award mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after January 16, 2010. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on January 8, 2013.

Synopsis

The sponsor invites applications for research projects that involve secondary data analyses or development of statistical methodology using existing genome-wide data, relevant to human dental or craniofacial conditions or traits. This program will use the NIH Small Research Grant (R03) award mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2010.

Synopsis

The sponsor provides support for applications that will use nonhuman primate models to study the oral biology of HIV infection and the oral complications associated with AIDS. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 16, 2008. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2011.

Synopsis

The sponsor provides support to conduct studies designed to develop innovative approaches that would contribute to understanding of the mechanisms that impact on the virulence of infections involving two or more microorganisms or strains of microorganisms (with the exception of HIV). This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

This program will expire on May 8, 2012, unless reissued.

Synopsis

The sponsor provides support for meritorious research projects that involve secondary data analyses using existing dental or craniofacial database resources. This program will use the Small Research Grant (R03) award mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2010.

Synopsis

The sponsor offers support for preliminary data collection, pilot or feasibility studies on oral health promotion research directed at improving oral health across the lifespan. The study team must include health promotion, behavioral and/or social scientists. This research on prevention of oral diseases and/or their sequelae could focus in any of the following areas: maternal and child health; adolescent and young adult health; and the health of adults with complex diseases in the general population or in subgroups of the population with health disparities. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2010.

Synopsis

The sponsor offers support for formation of partnerships and/or coalitions among stakeholders to develop a comprehensive research plan on health promotion for a specific oral disease or condition. The partnership or coalition should include individuals with extensive experience in health promotion, behavioral and/or social sciences. This plan would be based on previously collected epidemiological, behavioral, social and/or environmental data and the proposed research plan will inform a subsequent full scale R01-type study. The health research plan could address any of the following areas: a) apply or adapt existing behavioral or health promotion theories and planning research models to known risk factors and lifestyle aspects of oral diseases and conditions, b) promote optimal oral health of individuals, families and communities in the context of overall health and co-morbidities, and c) integrate oral health promotion into general health promotion programs. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applicants must obtain written approval from the NIDCR’s Director of the Division of Extramural Research (DER) or designee before submitting an R34 grant application. This letter must be included when submitting the R34 application. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on September 8, 2011.

Synopsis

The sponsor clinical trial planning (R34) grants for the comprehensive planning, design and documentation of investigator-initiated Phase I, II, III, or IV interventional clinical trials. Interventional behavioral studies, sometimes referred to as Stage I, II, III or IV studies, are included. The R34 planning grant is designed to: (1) permit early peer review of the rationale for the proposed clinical trial; (2) permit early assessment of the design and implementation plans of the proposed trial; and (3) provide support for the development of a comprehensive clinical trial protocol and associated documents including a Manual of Procedures. The complete protocol and associated documents are required components of any subsequent clinical trial implementation (U01) application. The product of the R34 will be either an application for a clinical trial implementation cooperative agreement (U01) or a report summarizing the work completed and the reasons for not proceeding to a clinical trial implementation application. This program will use the NIDCR Clinical Trial Planning (R34) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 16, 2009. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2012.

Synopsis

The sponsors invite applications to support the secondary analysis of existing data sets relevant to diabetes and endocrine and metabolic diseases; digestive diseases and nutrition, including obesity and eating disorders; and kidney, urologic, and hematologic diseases. The goal of this NIDDK program is to facilitate research that explores innovative hypotheses through the use of existing data sets. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after May 16, 2009. The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on May 8, 2012.

Synopsis

The sponsors invite exploratory/developmental clinical research related to the prevention or treatment of diabetes, obesity and endocrine and genetic metabolic diseases. The Pilot and Feasibility Clinical Research Grants Program is designed to allow initiation of exploratory, short-term clinical studies, so that new ideas may be investigated without stringent requirements for preliminary data. The short-term studies should focus on research questions that are likely to have high clinical impact. They can include testing a new prevention strategy, a new intervention, or unique combinations of therapies. A high priority is the use of such studies to help stimulate the translation of promising research developments from the laboratory into clinical practice in diabetes, endocrine diseases and genetic metabolic diseases, including cystic fibrosis. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Deadline Note

Applications may be submitted to Grants.gov in response to this announcement on or after September 16, 2009. The deadlines for receipt of standard R03 applications under this announcement are: February 16, June 16, and October 16 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on September 8, 2012.

Synopsis

The purpose of this program is to provide support for clinical scientists from underrepresented racial/ethnic backgrounds, disadvantaged backgrounds or clinical scientists with disabilities to conduct small research projects in the area of diabetes, endocrinology, metabolism, digestive diseases, hepatology, obesity, nutrition, kidney, urology, or hematology. The NIDDK and the ODS recognize the need to promote diversity in the health-related workforce by increasing the number of highly trained clinical researchers from diverse backgrounds conducting research in areas of importance to the NIDDK. This FOA is aimed at New Investigators who hold a health professional doctoral degree or other clinical doctoral degree AND who are from a group that have been shown to be underrepresented in biomedical research (see eligible PD/PI for full definition). This program will use the NIH Exploratory/Developmental (R03) grant mechanism.